论文部分内容阅读
为了定量测定非霍奇金淋巴瘤(NHL)中血清乳酸脱氢酶(LDH)、β2微球蛋白(β2-MG)及糖类抗原125(CA125)的临床意义,回顾分析65例经病理确诊的NHL患者的LDH、β2-MG及CA125,判断其与临床分期、治疗效果及预后的关系。结果:Ⅰ+Ⅱ期与Ⅲ+Ⅳ期,无症状组与有症状组、无骨髓浸润者与有骨髓浸润者相比,后者LDH和β2-MG均明显高于前者,差异有统计学意义,P<0.05。有浆膜腔积液及结外侵犯者,LDH和CA125明显高于无浆膜腔积液及结外侵犯者,经化疗缓解患者三者水平显著下降,P<0.05。LDH增高组与LDH正常组的2年生存率分别为90.1%和88.9%,差异无统计学意义,P>0.05;4年生存率分别为84.8%和25.2%,差异有统计学意义,P<0.05。CA125增高组与CA125正常组的2年生存率分别为87.6%和51.5%,差异有统计学意义,P<0.05。初步研究结果提示,血清LDH、β2-MG及CA125可能对NHL患者分期、预后及疗效判断有参考价值。
To quantitatively determine the clinical significance of serum lactate dehydrogenase (LDH), β2 microglobulin (β2-MG) and carbohydrate antigen 125 (CA125) in non-Hodgkin’s lymphoma (NHL), 65 patients with pathologically confirmed Of NHL patients with LDH, β2-MG and CA125, to determine its clinical stage, treatment and prognosis. Results: The LDH and β2-MG of the latter group were significantly higher than those of the former group in stage Ⅰ + Ⅱ and stage Ⅲ + Ⅳ, asymptomatic group and symptomatic group, with no bone marrow infiltration and those with bone marrow infiltration, the difference was statistically significant , P <0.05. There were serous effusion and extranodal aggression, LDH and CA125 were significantly higher than those without effusion and extranodal aggression, the level of chemotherapy-relieved patients decreased significantly, P <0.05. The 2-year survival rates of LDH elevated group and normal LDH group were 90.1% and 88.9%, respectively, with no significant difference (P> 0.05). The 4-year survival rates were 84.8% and 25.2%, respectively, with significant difference, P < 0.05. The 2-year survival rates of CA125 elevated group and CA125 normal group were 87.6% and 51.5%, respectively, with significant difference (P <0.05). Preliminary results suggest that serum LDH, β2-MG and CA125 may be NHL patients with staging, prognosis and therapeutic reference.